Strata to Help Clovis Find Patients for Prostate Cancer Trials of Rucaparib

Strata to Help Clovis Find Patients for Prostate Cancer Trials of Rucaparib
Strata Oncology will help Clovis Oncology accelerate patient enrollment in ongoing clinical trials assessing Clovis' rucaparib as a treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA or ATM mutations. Strata is conducting an observational study, the Strata Trial, which provides next-generation sequencing to all advanced cancer patients at affiliated cancer centers and hospitals. It refers patients with selected mutations to its pharmaceutical partners' clinical trials. Under the agreement with Clovis, Strata will refer prostate cancer patients with BRCA and ATM mutations to Clovis's TRITON2 and TRITON3 clinical trials. “We’re delighted to work with Cl
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *